loading
Promis Neurosciences Inc stock is traded at $0.92, with a volume of 45,636. It is up +1.88% in the last 24 hours and down -7.74% over the past month. ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$0.903
Open:
$0.93
24h Volume:
45,636
Relative Volume:
0.60
Market Cap:
$30.07M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-0.3538
EPS:
-2.6
Net Cash Flow:
$-22.23M
1W Performance:
-1.08%
1M Performance:
-7.74%
6M Performance:
-40.65%
1Y Performance:
-20.17%
1-Day Range:
Value
$0.9003
$0.95
1-Week Range:
Value
$0.87
$0.955
52-Week Range:
Value
$0.87
$3.10

Promis Neurosciences Inc Stock (PMN) Company Profile

Name
Name
Promis Neurosciences Inc
Name
Phone
416-847-6898
Name
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Name
Employee
7
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
PMN's Discussions on Twitter

Compare PMN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PMN
Promis Neurosciences Inc
0.92 30.07M 0 -563.30K -22.23M -0.1996
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Promis Neurosciences Inc Stock (PMN) Latest News

pulisher
Dec 18, 2024

ProMIS Neurosciences stock hits 52-week low at $0.88 - Investing.com

Dec 18, 2024
pulisher
Dec 02, 2024

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Down 16.6% in November - Defense World

Dec 02, 2024
pulisher
Nov 26, 2024

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewswire

Nov 26, 2024
pulisher
Nov 20, 2024

ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia

Nov 20, 2024
pulisher
Nov 16, 2024

ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

GREAT POINT PARTNERS LLC Acquires Shares in ProMIS Neurosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

ProMIS Neurosciences Inc (PMN) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in ProMIS Neurosciences Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

ProMIS Neurosciences Inc Reports Q3 2024 GAAP EPS of $0.31, Surp - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

ProMIS Reports Positive Phase 1a Results for Alzheimer's Drug, Secures $30.3M Financing | PMN Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 12, 2024

ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times

Nov 12, 2024
pulisher
Nov 06, 2024

ProMIS Neurosciences (STU:23J0) PensionAndRetirementBenefit : €0.43 Mil (As of Jun. 2024) - GuruFocus.com

Nov 06, 2024
pulisher
Oct 31, 2024

Biotech Shares Positive Phase I Data for Alzheimer's Treatment - Streetwise Reports

Oct 31, 2024
pulisher
Oct 31, 2024

Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com

Oct 31, 2024
pulisher
Oct 30, 2024

ProMIS Neurosciences Presents Positive Data from PMN310 - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference - StockTitan

Oct 30, 2024
pulisher
Oct 24, 2024

ProMIS Neurosciences, Inc. (NASDAQ:PMN): Among The 10 Oversold Canadian Stocks to Buy Right Now - Insider Monkey

Oct 24, 2024
pulisher
Oct 22, 2024

ProMIS Neurosciences stock hits 52-week low at $0.92 - Investing.com India

Oct 22, 2024
pulisher
Oct 21, 2024

ProMIS Neurosciences stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa

Oct 21, 2024
pulisher
Oct 13, 2024

ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now - Insider Monkey

Oct 13, 2024
pulisher
Oct 11, 2024

ProMIS Neurosciences appoints new CEO Neil Warma By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 10, 2024

ProMIS Neurosciences appoints new CEO Neil Warma - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

ProMIS Neurosciences Names Neil Warma Permanent CEO - TipRanks

Oct 10, 2024
pulisher
Sep 29, 2024

ProMIS Neurosciences (NASDAQ:PMN) versus Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head Analysis - Defense World

Sep 29, 2024
pulisher
Sep 25, 2024

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying - MSN

Sep 25, 2024
pulisher
Sep 25, 2024

Director Madge Shafmaster Acquires 200,000 Shares of ProMIS Neur - GuruFocus.com

Sep 25, 2024
pulisher
Sep 24, 2024

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Acquires 60,000 Shares - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $89,600.00 in Stock - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

ProMIS Neurosciences director Shafmaster purchases $255,750 in stock By Investing.com - Investing.com South Africa

Sep 24, 2024
pulisher
Sep 24, 2024

ProMIS Neurosciences director Shafmaster purchases $255,750 in stock - Investing.com India

Sep 24, 2024
pulisher
Sep 24, 2024

ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

BSE SME Popular Foundation slips on debut - Business Standard

Sep 24, 2024
pulisher
Sep 24, 2024

Popular Foundations shares list at IPO price on BSE SME platform - The Economic Times

Sep 24, 2024
pulisher
Sep 24, 2024

Popular Foundations makes tepid debut, shares list flat at ₹37 apiece on BSE SME platform - Upstox

Sep 24, 2024
pulisher
Sep 19, 2024

How To Check Popular Foundations IPO Allotment Status - NDTV Profit

Sep 19, 2024
pulisher
Sep 19, 2024

Taking a look at what insiders are doing to gauge the PureCycle Technologies Inc (PCT)’s direction - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

Popular Foundations IPO allotment to be finalized today - IPO Watch

Sep 19, 2024

Promis Neurosciences Inc Stock (PMN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Promis Neurosciences Inc Stock (PMN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Shafmaster Madge K.
Director
Sep 23 '24
Buy
1.28
70,000
89,656
138,333
Shafmaster Madge K.
Director
Sep 20 '24
Buy
1.25
60,000
75,066
68,333
GORDON MICHAEL S
10% Owner
Sep 16 '24
Buy
1.22
76,931
94,071
76,931
GORDON MICHAEL S
10% Owner
Sep 17 '24
Buy
1.40
16,292
22,809
93,223
Kirwin Patrick D.
Director
Aug 14 '24
Buy
1.25
10,000
12,492
62,983
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):